Compare Lamb Weston Holdings Inc (LW) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Lamb Weston Holdings Inc trades at $53.22 (market cap $7.31B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Lamb Weston Holdings Inc is far larger — about 7.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Lamb Weston Holdings Inc pays a 2.87% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| LW | MRVI | |
|---|---|---|
Market Cap | $7.31B | $977.37M |
Volume | 3,751,735 | 2,742,564 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $9.00 |
52-Week Low | $38.48 | $2.83 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $11.10B | $1.08B |
Dividend Yield | 2.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $51.96, up 3.55% today, showing strong momentum with four consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward trends, though RSI levels suggest potential overbought conditions. Fundamentally, the company maintains solid profitability with 14.17% ROE and 3.85% net margin, while trading at reasonable valuations of 28.39 P/E and 1.09 P/S ratios. Recent dividend payments of $0.38 demonstrate shareholder returns.
LW presents a balanced investment case with analyst consensus at $53.71 offering modest upside. The company's consistent earnings outperformance and cost-saving initiatives provide support, but declining profit margins from 18.85% in 2023 to 3.84% projected for 2026 represent significant headwinds. High debt levels at $3.68 billion and ongoing legal investigations create additional risk factors that warrant careful monitoring.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
